



Factor Therapeutics Appoints Transaction Advisor

Brisbane, Australia 16th October 2018: Factor Therapeutics Limited (ASX: FTT, the “Company”), an Australian biotechnology company developing therapeutics for advanced wound care, today announced that the Company has appointed Taylor Collison Limited to assist with ongoing partnering discussions and advising on its transactional options following a successful Phase 2 readout.

Factor Therapeutics is in advanced discussions with potential partners pending the outcome of the Company’s Phase 2 study of VF001 in venous leg ulcers (VLUs) and, following an extensive search and evaluation process involving both Australian and international firms, the Company has elected to appoint Taylor Collison based on their transaction experience in healthcare, relevant expertise in the wound care space and close working history with the Company.

Dr. Rosalind Wilson, CEO of Factor Therapeutics, stated, “We evaluated several US and European firms that would be capable of providing transaction support but, given the geographic range of potential partners and acquirers, we didn’t see a strong advantage working with an overseas firm rather than a domestic one, particularly one with a very close working relationship with the Company and familiarity with its financing history and shareholder base.”

Taylor Collison is a leading non-bank financial services firm providing a suite of services across equity capital markets (for corporate, institutional and retail clients) and corporate transactions. It has extensive corporate advisory expertise, across various sectors, in the areas of mergers, acquisitions, asset and business sales, joint ventures and partnerships. It has relevant experience in the biotech and healthcare sectors, having lead capital raisings for companies such as Ellex Medical Lasers, Telix Pharmaceuticals and RHS Limited (where it also advised on the recent acquisition by PerkinElmer Inc).

Dr. Cherrell Hirst, Chairman of Factor Therapeutics, added, “We’re delighted to have Taylor Collison supporting our engagement with potential partners. They have a proven track record in ASX biosciences and this appointment extends our collaboration with them at a significant inflection point in Factor’s journey, as we approach the Phase 2 readout.”

-ENDS-

Contact for Further Information:

Dr. Rosalind Wilson
Chief Executive Officer
Factor Therapeutics Limited
r.wilson@factor-therapeutics.com

About Factor Therapeutics

Factor Therapeutics Limited (“Factor”) is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company’s platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor’s shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <https://factor-therapeutics.com>